(Q38996973)

English

Overexpression of HepaCAM inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer

scientific article published on 8 May 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Overexpression of HepaCAM inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Xuedong Song

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Yin Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Hongfei Du

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Yanru Fan

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Xue Yang

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Xiaorong Wang

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Xiaohou Wu

7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Chunli Luo

8

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

8 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

74

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1023-1033

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Cloning and characterization of hepaCAM, a novel Ig-like cell adhesion molecule suppressed in human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Functional significance of the hepaCAM gene in bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Exon 2 methylation inhibits hepaCAM expression in transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Exploration of the correlations between interferon-γ in patient serum and HEPACAM in bladder transitional cell carcinoma, and the interferon-γ mechanism inhibiting BIU-87 proliferation

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Methoxychalcone inhibitors of androgen receptor translocation and function

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

The development of androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Castration-resistant prostate cancer: locking up the molecular escape routes

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Steroid hormone receptors in prostate cancer: a hard habit to break?

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Androgen receptor structural and functional elements: role and regulation in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Developments in nonsteroidal antiandrogens targeting the androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Blockade of testicular and adrenal androgens in prostate cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Targeting CYP17: established and novel approaches in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Mechanisms of androgen-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Androgen receptor signaling in androgen-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Expression of hepaCAM and its effect on proliferation of tumor cells in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Molecular biology of the androgen receptor

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

The MEK/ERK cascade: from signaling specificity to diverse functions

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22817

21 January 2018

Identifiers

10.1002/PROS.22817

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

release_vdlzu5swf5cctndeiajddbatvm

1 reference

https://api.fatcat.wiki/v0/release/vdlzu5swf5cctndeiajddbatvm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38996973&oldid=1966880324"